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Abstract: Head and neck squamous cell carcinoma (HNSCC) is a group of tumours which exhibit
low 5 year survival rates. Thus, there is an urgent need to identify biomarkers that may improve
the clinical utility of patients with HNSCC. Emerging studies support a role of toll-like receptors
(TLRs) in carcinogenesis. Therefore, this systematic review and meta-analysis was performed to
assess the prognostic value of TLR immunoexpression in HNSCC patients. We compiled the results of
thirteen studies comprising 1825 patients, of which six studies were deemed qualified for quantitative
synthesis. The higher immunoexpression of TLR-1 to 5 and 9 was associated with a worsening of the
clinical parameters of patients with HNSCC. Furthermore, induced levels of TLR-3, 4, 5, 7 and 9 were
found to predict the patients’ survival time. The meta-analysis revealed that TLR-7 overexpression
is associated with a decreased mortality risk in HNSCC patients (HR 0.51; 95%CI 0.13–0.89; I2
34.6%), while a higher expression of TLR-5 predicted shorter, but non-significant, survival outcome.
In conclusion, this review suggests that TLRs may represent some prognostic value for patients with
HNSCC. However, due to small sample sizes and other inherent methodological limitations, more
well designed studies across different populations are still needed before TLRs can be recommended
as a reliable clinical risk-stratification tool.
Keywords: toll-like receptors; head and neck squamous cell carcinoma; cancers; metastasis;
meta-analysis; biomarker; prognosis
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is a group of related tumours that develop in
the epithelial lining of the oral cavity, oropharynx, hypopharynx, and larynx [1]. Oral squamous cell
carcinoma (OSCC), for instance, is the 12th deadliest cancer type in the world, accounting for more than
90% of all HNSCC cases [2,3]. HNSCC is mainly associated with tobacco and alcohol consumption and
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has recently been associated with human papillomavirus (HPV) infection [3,4]. Despite the notable
advances in the treatment approaches of cancer patients, the 5 year survival rate of HNSCC patients
has not significantly improved in recent decades [4]. In fact, the use of prognostic factors has been one
of the important management strategies to guide the selection of an appropriate treatment plan for
HNSCC patients. However, the enormous heterogeneity of HNSCC tumours has limited the reliability
of most of the currently available prognostic markers [4]. Thus, there is an urgent need to identify new
prognosticators in HNSCC, and to assess whether they can serve as a guide for risk stratification and
treatment decisions.
Toll-like receptors (TLRs) are a group of transmembrane signalling proteins and pattern recognition
receptors that are expressed by cells and are an integral part of the innate immune system [5]. Thirteen
different TLRs were reported in mammals, of which 10 are expressed in humans [6]. Each of the TLRs are
characterised with distinctive functions in the body, e.g., TLR-2 and TLR-4 identify lipopolysaccharide
membrane components of Gram-negative bacteria, TLR-5 recognises bacterial flagellin, TLR-7 identifies
microbial nucleic-acid structures, while TLR-9 identifies microbial DNA-strands [5]. In this regard,
TLR-activating ligands are divided into two categories: pathogen-associated molecular patterns
(PAMPs), which are found in exogenous pathogens such as in microbes (viruses, bacteria, etc.); and
damage-associated molecular patterns (DAMPs), which are endogenously expressed from injured or
dying cells to regulate apoptosis, thereby upkeeping homeostasis [7].
Clinical studies showed that functional TLRs are expressed in a wide variety of malignant tissues
suggesting a crucial role of TLRs in tumorigenesis [8]. However, TLR signalling, by tumour and immune
cells, was shown to have a dual effect—inducing both tumorigenic and antitumorigenic effects [7,8].
For instance, it has been suggested that TLRs expressed on immune cells, during inflammation, can
mediate antitumoral effects, while these expressed on tumour cells can enhance cell proliferation and
anti-apoptotic effects during tumorigenesis [7].
Despite the intensive efforts to examine the usefulness of TLR expression as a survival
prognosticator in cancer patients, the results of many prognostic studies are not always consistent.
In this regard, meta-analysis compiles previous studies, and enhances the statistical power by pooling
the data from independent analyses [9]. Thus, in this study, we conducted a systematic review to identify
and critically appraise studies that have investigated the association between TLR immunoexpression
and the survival of HNSCC patients to date. In addition, we performed quantitative synthesis to assess
whether TLR immunoexpression can be used as a useful prognostic marker in HNSCC.
2. Results
2.1. Study Selection
The database search yielded a total of 655 studies. After the removal of duplicates, the titles
and abstracts of the remaining studies were screened against the eligibility criteria and 409 studies
were excluded as irrelevant. Then, the thirteen remaining studies were selected for further qualitative
analysis. Of these, six studies were deemed eligible to be analysed by the statistical synthesis.
The literature searching and screening process is illustrated in Figure 1.
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Figure 1. Flowchart diagram of the literature search and selection process.
2.2. Study Characteristics
Thirteen original research studies encompassing a total of 1825 patients were included in this
study. These studies were published between 2013 and 2020, and they were conducted in Finland
(n = 6), China (n = 5), Sweden (n = 1), and Germany (n = 1). The HNSCC histological subtypes
included oropharyngeal squamous cell carcinoma (OPSCC) [10,11], oral squamous cell carcinoma
(OSCC) [12–16], nasopharyngeal carcinoma (NPC) [17], base-of-tongue squamous cell carcinoma
(BOTSCC) [18], and oral tongue squamous cell carcinoma (OTSCC) [19–21]. Long et al. studied
samples from tongue SCC (TSCC), however, it was not specified whether they were obtained from
OTSCC or BOTSCC tissues [22]. The sample size per study ranged between 60 and 207 patients.
The immunostaining in these studies was conducted on formalin-fixed paraffin-embedded samples,
and targeted the following TLR subtypes: TLR-1 [17,22], TLR-2 [17,20], TLR-3 [12], TLR-4 [13,15,17,20],
TLR-5 [10,11,16–18,20,21], TLR-7 [11,14,17,18,20], and TLR-9 [11,17,19,20]. The main characteristics of
the included studies and the staining reagents are depicted in Tables 1 and 2, respectively.
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Table 1. General characteristics of the included studies.
Study Origin Tumour Type TumourStage Cases Age Study Period TLR
Compliance to
REMARK
[10] Finland OPSCC I–IV 143 HPV+ 60.8HPV− 62.2 (M) 2012–2016 TLR-5 Fulfilled all items
[12] China OSCC T1–T4 90 62.5 (M) 2005–2008 TLR-3 Lacked item No. 5
[17] Finland NPC I–IV 207 57 (M) 1990–2009 TLR-1, TLR-2, TLR-4,TLR-5, TLR-7, TLR-9 Fulfilled all items
[18] Sweden BOTSCC I–IV 77 62 (M) 2000–2011 TLR-5, TLR-7 Lacked item No. 5
[11] Finland OPSCC I–IV 331 - 2000–2009 TLR-5, TLR-7, TLR-9 Fulfilled all items
[13] China OSCC I–IV 110 60 (Med) 2006–2010 TLR-4 Lacked item No. 5
[22] China TSCC I–IV 60 57 (M) 2013–2015 TLR-1 Lacked items No. 1, 4, 5
[14] China OSCC I–IV 166 - 2000–2011 TLR-7 Lacked item No. 3
[19] Finland OTSCC 1–4 197 65 (Med) 1981–2009 TLR-9 Fulfilled all items
[20] Finland OTSCC I–IV 73 59 (Med) 1992–2002 TLR-2, TLR-4, TLR-5,TLR-7, TLR-9 Lacked item No. 5
[15] China OSCC T1–T4 61 59.31 (M) 1992–2007 TLR-4 Lacked items No. 4,5
[16] Germany OSCC I–IV 191 - - TLR-5 Lacked item No. 1
[21] Finland OTSCC 1–4 119 66 (Med) 1981–2009 TLR-5 Fulfilled all items
REMARK, Reporting Recommendations for Tumor Marker Prognostic Studies; HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell
carcinoma; NPC, nasopharyngeal carcinoma; BOTSCC, base-of-tongue squamous cell carcinoma; TSCC, tongue squamous cell carcinoma; OTSCC, oral tongue squamous cell carcinoma; M,
mean age; Med, median age.
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Table 2. Summary of the staining and evaluation methods.
Study Antibody Info Dilution Tissue Scoring Grade Cutoff Value
[10] TLR-5: (mAb, Mo), Novus 1:100 TMA Neg. 0, mild 1, moderate2, strong 3 Values (1–3) are scored as positive
[12] TLR-3: Abcam; clonality: ND 1:100 FFPE Low, high -
[17]
TLR-1: (Rb) Santa Cruz Bio. Inc. TLR-2: (pAb, Rb),
Santa Cruz. TLR-4: (pAb, Rb) Santa Cruz. TLR-5:
(mAb, Mo), Novus Biologicals. TLR-7: (pAb, Rb),
Imgenex/Novus Biologicals. TLR-9: (pAb, Rb),
Santa Cruz
TLR-1 1:100, TLR-2
1:200, TLR-4 1:300,
TLR-5 1:100, TLR-7
1:300, TLR-9 1:100
FFPE Neg., mild, moderate, orstrong
It is required that >80% of
tumour cells in the sample stained
positively
[18] TLR-5: (mAb, Mo), ImgenexTLR-7: (mAb, Rb), Imgenex
TLR-5 1:200
TLR-7 1:300 FFPE
Neg., weak, medium,
strong -
[11]
TLR-5: (mAb, Mo), Imgenex
TLR-7: (mAb, Rb), Imgenex
TLR-9: (pAb, Rb), Santa Cruz Bio. Inc.
TLR-5 1:200, TLR-7
1:300, TLR-9 1:100 TMA
0–3
(0 = none, 3 = strong) Values 1–3 are scored as positive
[13] TLR-4: (pAb, Rb) Boster Biological Tech Co. 1:150 FFPE Low, high IRS 3
[22] TLR-1: (pAb), Abcam 1:100 FFPE Percentage of stained cells0–4
IRS: low 0–3, high 2–4. The (%) of
stained cells was 0 for ≤ 25% staining; 1
for 25–50%; 2 for 50%; 3 for 51–75%;
and 4 for more than 75% staining
[14] TLR-7: Abcam; clonality: ND - FFPE Grade 1–3 Grade 1 (1–3) Grade 2 (4–6)Grade 3 (7–9)
[19] TLR-9: (mAb, Mo, IgG1), Imgenex 1:150 FFPE Low, high Histoscore: low 0–64, high 65–300
[20]
TLR-2: (pAb, Rb), Santa Cruz Bio. Inc. TLR-4: (pAb
Rb), Santa Cruz Bio. Inc. TLR-5: (mAb), Imgenex.
TLR-7: (pAb) Imgenex. TLR-9: (pAb), Santa Cruz
Bio. Inc.
TLR-2 1:50, TLR-4 1:50,
TLR-5 1:200, TLR-7
1:300, TLR-9 1:100
TMA
TLR-2, 4 and 7: 0–4
(0 = none, 4 = very high),
TLR-5 and 9: 0–3 (0 = neg.,
3 = strongly positive)
Low: none/mild
High: mod./strong
[15] TLR-4: Protein Tech & Affbiotect 1:150 FFPE Over-expressed,under-expressed 50%
[16] TLR-5: (mAb, Mo) (Imgenex) 1:100 FFPE Low expression; highexpression 7%
[21] TLR-5: (mAb, Mo, IgG2a), Imgenex 1:150 FFPE Weak and strongexpression
Histoscore: weak 0–135;
strong 136–300
FFPE, formalin-fixed paraffin-embedded; IRS, immunoreactive scoring; mAb, monoclonal antibody; Mo, mouse antihuman; Mod, moderate; ND, not disclosed; Neg, negative; pAb,
polyclonal antibody; Rb, rabbit antihuman; TMA, tissue microarray.
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2.3. Quality and Bias Assessment
For the quality assessment, five studies (38%) fulfilled all of the applied Reporting
Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria [10,11,17,19,21], while
the eight remaining studies had one or more missing items of the applied REMARK checklist
(Supplementary Table S1). Results from the Meta-Analysis of Statistics Assessment and Review
Instrument (MAStARI) critical appraisal tool revealed that all the included studies had no considerable
reporting bias. The risk of bias was moderate in two studies (15%) [12,21], and low in the remaining
eleven studies. Additional information can be found in Supplementary Table S2.
2.4. The Cutoff Values
The included studies employed different scoring methods to determine the cutoff values, including:
1) immunoreactive scoring (IRS), with grading from 0 to 12 [13], and IRS grading from 1 to 4 [22]; 2) a
histoscore was calculated by multiplying the intensity score by the percentage of positive cells, resulting
in a number between 0 and 300 [19,21]; 3) the receiver operating characteristics (ROC) analysis was
carried out by one study based on the highest diagnostic average of sensitivity and highest diagnostic
accuracy [16]. More information regarding the cutoff values and staining methods are listed in Table 2.
2.5. TLR and Clinicopathological Parameters of HNSCC Patients
The expression of TLR-1 was significantly correlated with advanced tumour–node–metastasis
(TNM) staging (p < 0.05) in patients with TSCC [22]. In NPC, TLR-1 positivity was strong in 82%
of the Finnish patient cohort, however, it had no correlation with the patients’ characteristics [17].
The expression of TLR-2 was also induced in 133/141 (94%) of the same cohort of NPC, and it was
significantly correlated with older patient age (p = 0.036) [17]. In another Finnish cohort of 73 OTSCC
patients, the higher expression of TLR-2 was correlated with deeper tumour invasion and grade
(p = 0.026; p = 0.021, respectively) [20]. A recent study by Han et al. reported that the higher expression
of TLR-3 was correlated with poorly differentiated tumour grades in OSCC patients [12]. In another
cohort of Chinese OSCC patients, cytoplasmic TLR-4 expression was significantly increased in the
tumour tissues and was correlated with deeper tumour invasion (p = 0.008), poor differentiation
(p = 0.034), and an advanced pathologic TNM stage (p = 0.008). [13]. In accordance with these findings,
Mäkinen et al. found that a higher TLR-4 expression in OTSCC tissues was correlated with deeper
tumour invasion (p = 0.008) and higher tumour grade (p = 0.005) [20]. Likewise, another study by
Ren et al. reported a significant correlation between the higher TLR-4 expression with tumour T-stage
(p = 0.005), clinical stage (p = 0.005), histological classification (p = 0.023) and lymph node metastasis
(p = 0.014) [15].
Interestingly, TLR-5 was the most studied subtype in the included reports. Recently, Kylmä et al.
found that higher TLR-5 immunoexpression was associated with advanced N-class (N1–N3; p = 0.008),
tumour site (tonsil; p = 0.006) and advanced tumour grade (grade 3; p = 0.004) in OPSCC tissues [10].
In another Finnish cohort of OPSCC patients, TLR 5 expression was more induced among current
smokers (p < 0.001) and alcohol abusers (p = 0.002), but less expressed in T1 tumours and regionally
advanced metastatic tumours of OPSCC patients [11]. However, although TLR-5 was associated with
older NPC patients, no statistically significant associations were found between TLR-5 and smoking,
TNM classification, or overall stage [17]. In OTSCC, a higher TLR-5 expression correlated with lower
tumour grade (p = 0.039) [20]. Grimm et al. found that the TLR-5 expression was not associated with
any clinicopathological characteristics of OSCC patients [16]. In OTSCC, higher TLR-5 was associated
with older age (>70 years at the time of diagnosis), female gender and disease recurrence (p < 0.05) [21].
On the contrary, no association between TLR-5 expression and tumour grade, stage or treatment was
found in OTSCC [21].
The expression of TLR-7 was significantly low in OPSCC patients with a history of smoking
and alcohol abuse [11]. However, higher TLR-7 was correlated with tumour site (p = 0.004), regional
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metastasis (p = 0.001) and advanced stages (p = 0.003) in patients with OPSCC [11]. In the same study,
higher TLR-9 expression was associated with current smoking (p < 0.001), but not with any other
clinical parameters [11]. Kauppila et al. found that higher TLR-9 immunoreactivity in OTSCC was
associated with poor tumour differentiation (p < 0.05) [19].
2.6. TLR and the Viral Status of HNSCC Patients
Five studies assessed the association between TLRs and the viral status of human papilloma virus
(HPV) and/or the Epstein–Barr virus (EBV) in HNSCC patients [10,11,17,18,20]. Kylmä et al. found
that higher TLR-5 expression was associated with poor disease-specific survival (DSS) in HPV-positive
OPSCC patients [10]. In agreement with this, higher TLR-5 and lower TLR-7 expression had worse
recurrence-free survival (RFS) and DSS in another Finnish cohort of OPSCC patients [11]. In NPC
patients, it was found that only TLR-2 and TLR-5 expressions were related to viral status, where
their expression was stronger in the HPV-positive and in the EBV/HPV-negative patients than in the
EBV-positive group (p < 0.0001) [17]. On the contrary, TLR-5 expression was markedly weaker in
HPV-positive BOTSCC patients (p < 0.001), while the opposite was observed for TLR-7 (p < 0.007) [18].
Mäkinen et al. reported that p16INK4a, a surrogate marker for HPV, did not correlate with TLR
expression in OTSCC patients [20].
2.7. TLR and the Survival Outcomes of HNSCC Patients
Five studies analysed the overall survival (OS) as the primary survival endpoint [12–14,17,20].
Other endpoint measures included disease-free survival (DFS), DSS (or cancer-specific survival, CSS)
and/or RFS. Study-specific endpoints are listed in Table 3. One report by Han et al. indicated that higher
TLR-3 expression was associated with shorter OS [12]. Likewise, higher TLR-4 expression predicted
shorter OS, DFS, DSS and post-operative survival in two Chinese studies conducted on patients
with OSCC [13,15]. A strong expression of TLR-5 predicted worse DSS and RFS in HPV-positive in
Finnish OPSCC patients [10,11]. Furthermore, a higher TLR-5 expression in OTSCC patients was
associated with reduced DFS outcomes [21]. However, Grimm et al. found no association between
TLR-5 expression and DFS in OSCC patients [16].
For TLR-7, Ruuskanen et al. found that NPC patients with a positive expression had better OS
than those with negative TLR-7 [17]. Interestingly, according to TLR-7 expression, the 5 year OS rates
were 66% (for mild expression) and 22% (for negative status) [17]. Moreover, the low expression of
TLR-7 predicted poor DSS and RFS in HPV-positive OPSCC patients [11]. Ni et al. reported that the
higher expression of TLR-7 in tumour cells was correlated with shorter OS in OSCC [14]. On the
contrary, higher TLR-7 in the stromal fibroblast-like cells (FLCs) correlated with a longer survival time
than the low expression group [14]. However, no statistically significant correlation was found between
TLR-5 and 7 with the clinical outcome or survival in BOTSCC patients [18]. One study revealed that
strong TLR-9 expression was an independent predictor of poor CSS [19].
Int. J. Mol. Sci. 2020, 21, 7255 8 of 18
Table 3. Summary of the prognostic data.
Study TLR Endpoint Adjusted Analysis Adjusted Factors Results Interpretation
[10] TLR-5 DSS HR = 2.5, P = 0.129,95% CI = 0.8–8.1
Gender, age, smoking, TN-class,
stage, treatment, HPV status
High TLR-5 expression was an independent indicator
of poor DSS in those with HPV-positive OPSCC. High
TLR-5 was significantly associated with LN-status,
tumour site and grade.
[12] TLR-3 OS - -
TLR-3 expression was associated with poor prognosis
and shorter OS. Higher TLR-3 was also associated
with pathologic grade.
[17]
TLR-1
TLR-2
TLR-4
TLR-5
TLR-7
TLR-9
OS
TLR-7: HR = 0.37,
P = 0.018,
95% CI = 0.16–0.84
Gender, age, ethnicity, smoking,
TN-class, stage, histology, virus
status, treatment, irradiation
technique
Patients with positive TLR-7 tumour expression had
better OS than those with no TLR-7 expression.
DSS
TLR-7: HR = 0.39,
P = 0.046,
95% CI = 0.15–0.98
[18] TLR-5
TLR-7
DSS - - TLR-5 or TLR-7 did not have a statistically significant
correlation with clinical outcome or survival.DFS -
[11]
TLR-5
TLR-7
TLR-9
DSS TLR-7: HR = 3.2,P = 0.027, 95% CI = 1.1–9.0 Gender, smoking, TN-class, HPV
status, treatment
High expression of TLR-5 and low expression of
TLR-7 are correlated with poor DSS and RFS of
HPV-positive patients.RFS -
[13] TLR-4
OS RR=2.334, P=0.006,95% CI=1.277-4.267
TN-stage, adjuvant therapy,
differentiation, invasion depth,
cytoplasmic and nuclear NF-kBp65
High TLR-4 expression was an independent
prognostic factor and significantly associated with
lower DFS, DSS and OS. High TLR-4 expression was
correlated with pTNM-stage, differentiation and
invasion.
DSS RR=2.495, P=0.005,95% CI=1.321-4.712
DFS RR=2.888, P=0.001,95% CI=1.532-5.443
[22] TLR-1 - - -
TLR-1 plays an inhibitory role in the development and
progression of TSCC. High TLR-1 was correlated with
TNM-staging.
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Table 3. Cont.
Study TLR Endpoint Adjusted Analysis Adjusted Factors Results Interpretation
[14] TLR-7
OS HR = 1.253, P = 0.547 (NS),95% CI = 0.601–2.613 Gender, age, smoking, TNM-stage,
differentiation, LNM, inflammation
High expression of TLR-7 in tumour cells correlated
with shorter OS but not with DFS. On the contrary,
high TLR-7 in stromal fibroblast-like cells was
correlated with better survival time. High TLR-7 was
also significantly associated with tumour
differentiation.
DFS -
[19] TLR-9 CSS HR = 1.810, P = 0.024,95% CI = 1.053–3.112 Age, tumour stage, histologic grade
High TLR-9 expression was an independent predictor
of poor CSS. TLR-9 correlates significantly with
tumour grade.
[20]
TLR-2
TLR-4
TLR-5
TLR-7
TLR-6
OS - Pathologic T-stage, grade, presence
of occult neck metastases,
and invasion
Negative or mild TLR-5 expression was related to
worse DSS.
DSS -
DFS -
[15] TLR-4 POS - -
Patients with TLR-4 amplification had a shorter POS
and high TLR-4 expression also correlates with
T-stage, histological classification and metastasis.
[16] TLR-5 DFS - -
TLR-5 expression was not associated with any
clinicopathological characteristics or impact on
survival.
[21] TLR-5
DFS HR = 3.587,95% CI = 1.632–7.882
Gender, age, stage, histologic grade,
adjuvant therapy
Strong TLR-5 expression was independent prognostic
factor associated with reduced DFS and CSS.CSS -
CSS, cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; LN, lymph node; LNM, lymph node metastasis; OS, overall survival; POS,
post-operative survival; pTNM, pathologic tumour-node-metastasis; RFS, recurrence-free survival; RR, risk ratio; T., tumour; TLR, toll-like receptor; TN, tumour-node; TSCC, tongue
squamous cell carcinoma.
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2.8. Meta-Analysis Results
Among thirteen studies selected for the qualitative analysis, seven studies were excluded because of
insufficient data for quantitative synthesis. When the remaining six studies were combined, regardless
of the TLR subtype and endpoint, TLR was associated with a small non-statistically significant reduced
survival (HR 0.96, 95% CI 0.39–1.54; I2 61.8%, p-value for I2 = 0.0015) (Figure 2; Table 4). Then, we
performed a subgroup analysis of the studies based on the reported TLR subtype. Studies reporting
TLR-5 (n = 2) and TLR-7 (n = 4) were adequately powered and eligible for the pooled analysis. As a
result, higher TLR-5 expression was associated with an increased non-statistically significant risk of
mortality (HR 3.13, 95%CI 0.76–5.50; I2 0.0%, p-value for I2 = 0.657), while higher TLR-7 was associated
with a statistically significant decreased risk of mortality in HNSCC patients (HR 0.51, 95%CI 0.13-0.89;
I2 34.6%, p-value for I2 = 0.205) (Figure 3; Table 4). Studies were further analysed according to the
survival endpoints, however, it was not possible to obtain meaningful results because of the differences
in the applied scoring categories per respective measure.
Figure 2. Forest plot of the association between toll-like receptors (TLR) and survival outcomes in
HNSCC patients (random-effects model). HR, hazard ratio; CI, confidence intervals.
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Table 4. Results from the meta-analysis.
Study Number ofCases Country TLR Type Endpoint
Hazard Ratio
(95% CI) Relative Weight, %
All Studies
[21] 119 Finland TLR-5 DFS 3.59 (1.63–7.88) 2.00
[10] 143 Finland TLR-5 DSS 2.50 (0.80–8.10) 3.09
[11] 331 Finland TLR-7 DSS 3.20 (1.10–9.00) 16.33
[14] 166 China TLR-7 OS 1.25 (0.60–2.61) 2.32
[17] 207 Finland TLR-7 DSS 0.39 (0.15–0.98) 16.75
[17] 207 Finland TLR-7 OS 0.37 (0.16–0.84) 30.51
[19] 197 Finland TLR-9 CSS 1.81 (1.05–3.11) 29.00
Pooled overall estimate 0.96 (0.39–1.54) 100.00
Heterogeneity measures I-squared = 61.8% (p-value = 0.0015), Tau-squared = 0.2533
Subgroup Analysis (TLR subtype)
Study Number ofCases Country TLR Type Endpoint
Hazard Ratio
(95% CI) Relative Weight, %
TLR-5 Studies
[21] 119 Finland TLR-5 DFS 3.59 (1.63–7.88) 57.70
[10] 143 Finland TLR-5 DSS 2.50 (0.80–8.10) 42.30
Pooled overall estimate 3.13 (0.76–5.50) 100.00
Heterogeneity measures I-squared = 0.0% (p-value = 0.657), Tau-squared = 0.000
TLR-7 Studies
[11] 331 Finland TLR-7 DSS 3.20 (1.10–9.00) 0.91
[14] 166 China TLR-7 OS 1.25 (0.60–2.61) 11.98
[17] 207 Finland TLR-7 OS 0.37 (0.16–0.84) 47.27
[17] 207 Finland TLR-7 DSS 0.39 (0.15–0.98) 39.84
Pooled overall estimate 0.51 (0.13–0.89) 100.00
Heterogeneity measures I-squared = 34.6% (p-value = 0.205), Tau-squared = 0.0489
DSS, disease-specific survival; OS, overall survival; TLR, toll-like receptor.
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Figure 3. Forest plot demonstrating a subgroup analysis of the association between the studied subtype
of toll-like receptor (TLR) and survival outcomes in HNSCC patients (random effects model). HR,
hazard ratio; CI, confidence intervals.
3. Discussion
In the present meta-analysis, we compiled and summarised the results of thirteen clinical
studies comprising a total of 1825 patients, of which six studies with collectively 1163 patients were
deemed qualified for further quantitative synthesis. These studies assessed the prognostic value of
TLR-immunoexpression in HNSCC (Figure 4). A higher immunoexpression of TLR-1 to 5, 7, and 9
was significantly correlated with at least one worsening clinical parameter and/or the viral status
of patients with HNSCC. Furthermore, a shorter survival outcome was predicted by an induced
expression of TLR-3, 4, 5 and 9, while TLR-7 predicted a favourable prognosis in most relevant
studies. This was further analysed by subgroup meta-analysis, which confirmed the prognosticator
role of TLR-7 in HNSCC. The higher expression of TLR-5 predicted shorter survival outcomes,
however, our meta-analysis revealed no significant evidence to support such a role. Likewise, there
were no statistically significant effects of TLRs when all studies were combined, regardless of the
receptor subtype.
To our knowledge, this is the first meta-analysis report assessing the prognostic value of different
TLRs in patients with HNSCC. Among the strengths of our study that our review protocol was
developed as recommended by PRISMA guidelines, which was registered in PROSPERO prior to
conducting this study. In addition, we were able to conduct quantitative analyses due to an adequate
number of eligible studies. Most of these studies fulfilled, by and large, the applied REMARK criteria
and exhibited low scores of reporting bias (Table 2 and Supplementary Table S2). Furthermore, there
was less variation among studies regarding the clinicopathological features, immunodetection reagents
and staining methods. However, several limitations should be considered while interpreting the
results of this study, such as the small sample sizes and limited number of studies per some receptor
subtypes. In addition, we were not able to find any prognostic data on TLR-6 or 8 in HNSCC patients.
Due to the lack of adequate estimates, we only managed to include 46.1% of the primary studies in
the quantitative synthesis. A considerable heterogeneity (I2 > 60%) was detected when all studies
were combined, which could arise from variabilities in TLR subtype, tumour site, and the estimated
endpoints. Finally, since most studies were conducted in limited populations (i.e., Finnish or Chinese),
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this may hinder the robustness of such association estimates. Hence, the results should be interpreted
cautiously as they may bear limited feasibility for clinical stratification approaches.
Figure 4. An illustration of the studied toll-like receptors (TLRs) in the corresponding tumour site of
the head and neck squamous cell carcinoma patients included in the present review.
TLRs are crucial mediators of inflammatory responses, which can promote carcinogenesis
through different molecular mechanisms [23]. In this regard, inflammation-associated molecular
patterns (i.e., PAMPs and DAMPs), which signal via TLRs, play different roles in the development of
HNSCC [24]. For instance, TLR-5 recognises bacterial flagellin, which can influence tumour growth and
progression in vitro [25,26]. On the other hand, the activation of TLR-7 can induce Type 1 interferon
and inflammatory response, and hence represents a promising target for antiviral and antitumour
therapy [27]. Indeed, tumorigenesis and tumour metastasis are complex multistep processes, which
involve the differential upregulation and downregulation of multiple genetic and epigenetic signalling
pathways [28]. In the present review, the clinical studies revealed differential expressions of the TLR
family in various HNSCC tumours, of which TLR-3, 4, 5, 7 and 9 had certain prognostic values in their
respective tumours. Recently, we also reported an altered expression of TLRs in oral lichen planus—a
potentially premalignant lesion of HNSCC [29,30].
The correlation between the expression of TLR subtypes and the outcome of patients has also
been investigated in other common carcinomas. Oesophageal SCC (ESCC), for instance, ranks seventh
in terms of cancer incidence and shares broad similarities with HNSCC [31,32]. In ESCC, TLR-3
overexpression was significantly correlated with worse clinical parameters, while higher levels of TLR-9
were positively associated with advanced tumour grade, lymph node and distant metastases [33,34].
A similar prediction of worse outcome was also reported for TLR-4 in patients with pancreatic
adenocarcinoma, where its higher expression was significantly associated with a shorter OS [35].
Interestingly, these reports are in agreement with the findings of the HNSCC studies included in this
review [12,13,15,19]. However, the prognostic values of TLRs were not always consistent between
different studies. For instance, Sato et al. found that ESCC patients expressing higher levels of TLR-3
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had better survival outcomes [36]. Likewise, higher TLR-4 expression in ESCC patients was associated
with better survival compared with weaker expression [37].
Conflicting results in the prognostication value of TLRs may likely arise from several key factors,
such as differences in clinical characteristics, cancer type, cutoff values and the detection methods
of TLRs. In this regard, most of the studies reported a worse survival outcome in association with a
higher TLR-5 expression [10,11,21]. However, one study found that negative or mild TLR-5 expression
predicted poor survival in OTSCC, while two other studies did not find any significant correlation
between TLR-5 expression and patient survival [16,18,20]. These conflicting results could also be
explained by the HPV status, which is probably negative in OSCC rather than OPSCC patients [11].
On the other hand, TLR-7 was associated with favourable prognosis in HNSCC, which was further
confirmed by our meta-analysis. Although high TLR-7 expression in OSCC cells predicted poor
survival time, Ni et al. found that high TLR-7 in stromal FLCs plays an antineoplastic role during oral
carcinogenesis [14]. In fact, such a finding could in part be attributed to the promising antitumour
effect of TLR-7 in various cancers, such as OSCC, breast cancer and lymphoma [38–40].
In conclusion, most studies in this review indicated a differential expression of TLRs in HNSCC,
which was correlated with worsening clinical parameters and/or survival. Of these receptors, TLR-7 may
represent a prognostic value in HNSCC, particularly for patients with OPSCC. Altogether, these findings
support the putative role of TLRs in tumorigenesis. However, due to the aforementioned inherent
methodological limitations, more well designed studies with larger sample sizes across different
populations are needed before TLRs can reliably be recommended for clinical staging approaches.
4. Materials and Methods
4.1. Protocol and Registration
The protocol of this study was developed in accordance with the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [41], which was prospectively
registered in the International Prospective Register Of Systematic Reviews PROSPERO (https://www.
crd.york.ac.uk/prospero/) [42].
4.2. Inclusion and Exclusion Criteria
Studies were eligible for inclusion when the following criteria were met: (1) original research
articles conducted on human tissue samples; (2) patients diagnosed with HNSCC; (3) the relationship
between TLR immunoexpression and the clinical or survival outcomes was assessed. Studies were
excluded if they were case reports, case series, editorials, reviews, or involving animals. The detailed
inclusion and exclusion criteria are listed in Table 5.
Table 5. Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
Original research articles The retrieved records were case reports; reviews;letters; etc.
Histological tissue samples from human patients Animal model studies and tests
Patients diagnosed with HNSCC Articles not written in English language
Studies reported the association between TLR
immunoexpression and the survival outcomes
Insufficient information of the correlation between
clinical features and/or survival outcomes
HNSCC, head and neck squamous cell carcinoma; TLR, toll-like receptor.
4.3. Search Strategy and Study Screening
Studies were searched from the inception until the 11th of May 2020 using the following electronic
databases: PubMed, Cochrane, Scopus and Web of Science. We implemented the following search
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terms, adapting accordingly to the respective databases: (“Toll-like receptors” OR “Toll like receptors”
OR “TLR”) AND (“head and neck neoplasms” OR “head and neck cancer” OR “head and neck
squamous cell cancer” OR “oral cancer” OR “mouth neoplasms” OR “laryngeal neoplasms” OR
“gingival neoplasms” OR “lip neoplasms” OR “palatal neoplasms” OR “tongue neoplasms” OR
“pharyngeal neoplasms” OR “squamous”) AND (prognos* OR predict* OR surviv* OR recur* OR
mortal* OR metasta*). No search restrictions were applied for the date of publication or language.
The resulted articles were then imported to RefWorks, where duplicates were removed. Then, studies
were screened by title and abstract to fulfil the eligibility criteria listed in Table 1. Thenceforth,
full articles were retrieved for further qualitative review. The literature screening was conducted
independently by two reviewers (SH and RH). A third reviewer (AS) intervened if there were any
disparities between the results.
4.4. Data Extraction and Study Items
We first developed a data extraction form, which was used by the same two reviewers (SH and
RH) to extract the following key items from the included studies: study’s title, first author name,
and year of publication; patient characteristics; type of patient’s sample; tumour-related characteristics
(type, stage, grade, location); the studied TLR subtype; TLR scoring/expression findings; cutoff value;
antibody-related information (dilution, company, etc.); study period; follow-up durations; outcome
measures; endpoint of survival analysis; and estimates of prognosis such as hazard ratio (HR) with
their respective 95% confidence interval (CI) and p values, and the study’s main conclusions.
4.5. Assessment of Study Quality and Reporting Bias
Data reporting quality has been assessed using the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) guidelines [43]. Six assessment items were adapted from the REMARK
checklist as they were evinced to be applicable for our study, as follows: (1) patient samples; (2)
clinical data of the studied cohort; (3) immunohistochemical methods; (4) prognostic and survival data;
(5) applied statistics; and (6) classical prognostic factors. These applied REMARK items are detailed in
Supplementary Table S1. Two reviewers (SH and RH) independently analysed the risk of bias of the
included studies by employing the Meta-Analysis of Statistics Assessment and Review Instrument
(MAStARI) tool as we recently described [44]. The analysis report was derived from a ten-question
critical appraisal form aimed to determine the extent of bias in the study’s design, conduct and analysis
(Supplementary Table S2). Discrepancies within the results were resolved by discussion with a third
reviewer (AS). Discrepancies resulted in general from data overlooking or misunderstanding, and thus
they were easily resolved without too much discussion.
4.6. Data Synthesis and Statistical Analysis
Descriptive tables were used to summarise the characteristics of the included studies, as well as
presenting their derived quality grades obtained on the basis of the REMARK framework [43]. Both
narrative and quantitative syntheses were performed to summarise our results. The quantitative synthesis
involved conducting a random-effects meta-analysis of the studies judged to be reasonably homogenous
with regards to their consistency in methodology and definitions. The random-effects model was
undertaken using the DerSimonian–Laird estimate of the variance of the effect sizes. The weights assigned
to the studies in the meta-analysis were based on the inverse variance method, that is, weight = 1 divided
by the square of the standard error of the effect estimate. We first performed a meta-analysis of all studies
combined together regardless of their TLR subtypes. Then, we performed subgroup analysis by TLR
subtype (separately for TLR-5 and TLR-7 studies) and by survival endpoint. We quantified heterogeneity
between studies using the I-squared (I2) statistic, which quantifies the percentage of variance in the pooled
estimates that is attributable to differences in estimates between the meta-analysed studies rather than
due to chance. We estimated the between-study variance using the Tau-squared (T2) statistic, which
was derived from the DerSimonian–Laird estimate. All tests were 2-sided, and p < 0.05 was considered
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statistically significant. The meta-analyses were performed using Stata 14 (StataCorp. 2015. Stata Statistical
Software: Release 14. College Station, TX, USA: StataCorp LP).
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